Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
Dutasteride at 2.5mg is considered a potential hair loss cure due to its DHT-blocking ability, but there are concerns about side effects and individual responses. Minoxidil, finasteride, and RU58841 are also discussed, with mixed opinions on their effectiveness and safety.
The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.
Topical dutasteride is considered for hair loss, but concerns about systemic absorption and side effects like reduced libido are common. Users have mixed results, with some preferring oral finasteride or dutasteride despite side effects, while others find topical treatments beneficial but challenging.
RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.
KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
The conversation concludes that finasteride, a 5α-Reductase inhibitor used for hair loss, does not impair cognition either short-term or long-term. It suggests "brain fog" is not caused by the medication.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.
Dutasteride mesotherapy showed increased hair density and diameter without reducing serum DHT levels in a small study. However, the sample size was too small to make definitive claims about its efficacy.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
The conversation discusses whether it's better to start hair loss treatment with finasteride or dutasteride. Opinions vary, but many suggest starting with finasteride due to its shorter half-life and easier management of side effects, while others argue dutasteride is more effective and has fewer side effects.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
_the_orange_box_'s experience using oral minoxidil, with discussion about finasteride and the potential side effects of both treatments. Other users shared their own experiences related to hair loss treatments.
Genetic factors, enzyme activity, and DHT sensitivity affect individual responses to hair loss treatments like finasteride, minoxidil, and dutasteride. Starting treatments early can slow hair loss, but results vary among individuals.
Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
The conversation is about overcoming fear of finasteride/dutasteride for hair loss treatment. Users suggest starting with a small supply, noting side effects are rare and reversible, and emphasize personal comfort and confidence.
User is using topical Minoxidil (100 mg/day) and Finasteride (1 mg/day) but experiencing hair growth everywhere except the top of the scalp. They seek advice on improving scalp hair regrowth.
A 21-year-old male managed to control his hair loss using Nizoral, RU58841, and finasteride, but experienced increased scalp itchiness after starting creatine, which subsided upon stopping creatine. Users shared mixed experiences on whether creatine affects hair loss, with some reporting negative effects and others seeing no change or defending its benefits.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
The user tried dutasteride for hair loss for 2.5 years but experienced drastic thinning and receding hairline. They decided to switch back to finasteride, along with minoxidil, LLLT, and ketoconazole, due to dissatisfaction with dutasteride's results and side effects.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.